Merck & Co Inc MRK:NYSE
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
|---|---|---|---|---|
| 56.80 | 0.06 0.11% | 3.10% | 10,140,975 | 8.3M |
Recent News Headlines for Merck & Co Inc
- Merck Announces Second-Quarter 2014 Financial Results
-- Second-Quarter 2014 Non-GAAP EPS of $0.85, Excluding Certain Items, and GAAP EPS of $0.68 -- 2014 Full-Year Non-GAAP EPS Target of $3.43 to $3.53, Excluding Potential
- Merck Announces Second-Quarter 2014 Financial -2-
Animal Health sales totaled $872 million for the second quarter of 2014, a 2 percent increase compared with the second quarter of 2013, including a 1 percent negative impact due to foreign exchange. The growth was primarily driven by BRAVECTO (fluralaner), a chewable tablet that kills fleas and ticks in dogs for up to 12 weeks, which launched in Europe and the United States, as well as higher sales in poultry and aqua products. This growth was partially offset by the loss of sales of ZILMAX (zilpaterol hydrochloride), a feed supplement for beef cattle. The company decided last year to voluntarily suspend sales of ZILMAX in the United States and Canada. Excluding the impact of the ZILMAX sales suspension, Animal Health sales increased 9 percent in the second quarter.
- Merck Announces Second-Quarter 2014 Financial -3-
------------------------------------------------ -------------------- Gain on sale of ophthalmics business (500) to (550) ----------------------------------------------- --------------------
- Merck Announces Second-Quarter 2014 Financial -4-
- Merck Announces Second-Quarter 2014 Financial -5-
- Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients
- Merck Announces Fourth-Quarter 2014 Dividend
- Financial Results, Campaign Launch, and New Steps in Facility Planning - Research Reports on Johnson & Johnson, Merck, AstraZeneca, Novartis and Teva
- Technical Pointers on Pharma Equities -- AbbVie, Johnson and Johnson, Merck, Bristol-Myers Squibb, and Eli Lilly
- Merck's HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis and Positive Women's Network - USA to Encourage Women Living with HIV to be "Vocal" about their Treatment
- New Board Director, Clinical Trial Results, New Drug Designations and Marketing Authorizations - Analyst Notes on Johnson & Johnson, Merck, Novartis, GSK and Endo